Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M108,304Revenue $M15,879Net Margin (%)12.6Z-Score5.8
Enterprise Value $M108,832EPS $1.2Operating Margin %16.3F-Score6
P/E(ttm))54.3Cash Flow Per Share $2.8Pre-tax Margin (%)15.0Higher ROA y-yN
Price/Book7.310-y EBITDA Growth Rate %-1.3Quick Ratio1.5Cash flow > EarningsY
Price/Sales6.85-y EBITDA Growth Rate %-14.5Current Ratio1.7Lower Leverage y-yY
Price/Cash Flow11.7y-y EBITDA Growth Rate %-21.1ROA % (ttm)5.8Higher Current Ratio y-yY
Dividend Yield %2.2Insider Buy (3m)0ROE % (ttm)13.2Less Shares Outstanding y-yN
Payout Ratio %121Shares Outstanding M1,662ROI % (ttm)5.7Gross Margin Increase y-yY

Gurus Latest Trades with BMY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYBrian Rogers 2015-03-31 Reduce-0.09%$58.48 - $68.47
($62.6)
$ 65.805%Reduce -7.18%5,814,800
BMYVanguard Health Care Fund 2014-12-31 Add0.08%$48.92 - $61.3
($56.49)
$ 65.8014%Add 1.50%39,056,361
BMYIrving Kahn 2014-12-31 Add0.01%$48.92 - $61.3
($56.49)
$ 65.8014%Add 2.71%28,400
BMYMario Gabelli 2014-12-31 Add$48.92 - $61.3
($56.49)
$ 65.8014%Add 1.35%709,715
BMYDodge & Cox 2014-12-31 Add$48.92 - $61.3
($56.49)
$ 65.8014%Add 0.66%91,028
BMYRuane Cunniff 2014-12-31 Buy $48.92 - $61.3
($56.53)
$ 65.8014%New holding3,670
BMYRonald Muhlenkamp 2014-12-31 Reduce$48.92 - $61.3
($56.49)
$ 65.8014%Reduce -0.09%212,290
BMYKen Fisher 2014-12-31 Reduce$48.92 - $61.3
($56.42)
$ 65.8014%Reduce -39.96%30,739
BMYVanguard Health Care Fund 2014-09-30 Add0.3%$47.86 - $51.96
($49.97)
$ 65.8024%Add 6.31%38,480,761
BMYJoel Greenblatt 2014-09-30 Sold Out -0.05%$47.86 - $51.96
($49.97)
$ 65.8024%Sold Out0
BMYVanguard Health Care Fund 2014-06-30 Add0.86%$46.59 - $52.19
($49.29)
$ 65.8025%Add 22.96%36,197,961
BMYJoel Greenblatt 2014-06-30 Buy 0.05%$46.59 - $52.19
($49.29)
$ 65.8025%New holding89,363
BMYKen Fisher 2014-06-30 Add$46.59 - $52.19
($49.29)
$ 65.8025%Add 216.10%49,732
BMYRonald Muhlenkamp 2014-03-31 Buy 1.9%$48.54 - $56.61
($53.23)
$ 65.8019%New holding212,015
BMYVanguard Health Care Fund 2014-03-31 Add0.73%$48.54 - $56.61
($53.21)
$ 65.8019%Add 20.35%29,437,761
BMYGeorge Soros 2014-03-31 Sold Out -0.05%$48.54 - $56.61
($53.23)
$ 65.8019%Sold Out0
BMYJoel Greenblatt 2014-03-31 Sold Out -0.02%$48.54 - $56.61
($53.23)
$ 65.8019%Sold Out0
BMYJoel Greenblatt 2013-12-31 Buy 0.02%$46.41 - $53.84
($50.96)
$ 65.8023%New holding11,679
BMYVanguard Health Care Fund 2013-09-30 Add0.64%$41.32 - $47.53
($43.84)
$ 65.8033%Add 20.26%24,459,861
BMYIrving Kahn 2013-09-30 Reduce-0.19%$41.32 - $47.53
($43.84)
$ 65.8033%Reduce -48.95%28,300
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Schmukler Louis SPres., Global Mfg. & Supply 2015-03-16Sell12,000$66.96-1.43view
Cuss Francis MEVP & CSO 2015-03-16Sell114,666$67.81-2.67view
Moed Samuel JSVP, Strat Plan & Analysis 2015-03-13Sell591$66.67-1view
Moed Samuel JSVP, Strat Plan & Analysis 2015-03-10Sell10,343$65.840.24view
Elicker John ESVP Pub Affairs & Inv Relation 2015-03-06Sell10,468$66.24-0.36view
LEUNG SANDRAGeneral Counsel & Secretary 2015-02-17Sell11,746$60.399.29view
Moed Samuel JSVP, Strat Plan & Analysis 2015-02-12Sell3,880$59.2611.37view
Moed Samuel JSVP, Strat Plan & Analysis 2015-02-06Sell21,478$60.159.73view
CORNELIUS JAMES MDirector 2015-01-30Sell50,000$60.68.91view
Schmukler Louis SPres., Global Mfg. & Supply 2015-01-29Sell5,250$60.738.68view

Press Releases about BMY :

    Quarterly/Annual Reports about BMY:

    News about BMY:

    Articles On GuruFocus.com
    HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 
    Bristol-Myers Signs An Exclusive Pact In Gene Therapy For Treating Cardiovascular Disorders Apr 08 2015 
    Piper Jaffray Sees Potential in uniQure NV (QURE) and Bristol-Myers Squibb (BMY) Collaboration Apr 07 2015 
    Vanguard Health Care Fund Comments on Bristol-Myers Squibb Company Mar 27 2015 
    Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
    Weekly Insider Sells Highlight: MHK, JAZZ, BMY, ZAYO Mar 23 2015 
    Top Pharma Stock Picks For March Mar 13 2015 
    Johnson & Johnson Unfazed By $25 Million Fine Mar 13 2015 
    Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
    Abner Herrman's Top Three Holdings Feb 26 2015 


    More From Other Websites
    EU regulators warn against combining hep C drugs with amiodarone Apr 24 2015
    EU regulators warn against combining hep C drugs with amiodarone Apr 24 2015
    Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for... Apr 24 2015
    7:46 am Bristol-Myers Squibb confirms positive CHMP opinion in the European Union for Opdivo... Apr 24 2015
    Final Glance: Pharmaceuticals companies Apr 23 2015
    Final Glance: Pharmaceuticals companies Apr 23 2015
    Midday Glance: Pharmaceuticals companies Apr 23 2015
    Midday Glance: Pharmaceuticals companies Apr 23 2015
    Early Glance: Pharmaceuticals companies Apr 23 2015
    Early Glance: Pharmaceuticals companies Apr 23 2015
    First Randomized Study Evaluating Opdivo (nivolumab)+Yervoy (ipilimumab) Regimen Demonstrates... Apr 21 2015
    Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog Apr 21 2015
    Cardinal Health’s $27M settlement causes rift at Federal Trade Commission Apr 21 2015
    Top Analyst Upgrades and Downgrades: GE, IBM, Bristol-Myers, Encana, Halliburton, Rio Tinto,... Apr 21 2015
    Morgan Stanley Says 'Buy The Leader In IO,' Upgrades Bristol-Myers To Overweight Apr 21 2015
    Bristol-Myers upgraded by Morgan Stanley Apr 21 2015
    Bristol-Myers Drug Combination Shows Promise Against Melanoma Apr 20 2015
    Merck's Keytruda Tops Melanoma, Lung Cancer Studies - Analyst Blog Apr 20 2015
    Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog Apr 20 2015
    Bristol, Merck Cancer Drugs Strut Their Stuff Apr 20 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK